COMPANY

Zetagen Therapeutics, Inc.

Keywords: oncology cancer metastatic cancer small molecule Metastatic Breast Cancer in the Spine Cervical Radiculopathy Myelopathy Cervical Neurological Abnormality Disc Disease Disc Degeneration ZetaMet™ (ZetaFuse™ Bone Graft)

Location: Syracuse, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $12.91M · announced Nov 25, 2025 Company release ↗
Source quote
- Nov 25, 2025 · Company release ↗
  “— Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, today announced the successful closure of its Series B1 financing round of $12,908,000.”

Raises announced in these releases: $12.91M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 25, 2025 Raise Series B · $12.91M source ↗
Sep 1, 2022 Trial start Phase 2: ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES source ↗
2026-09 Trial start Not phased (device or behavioral study): Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05280067	ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES	Phase 2	Completed	Sep 1, 2022	Oct 10, 2025 (actual)
NCT05971329	Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease	Not phased (device or behavioral study)	Recruiting	2026-09	2026-09 (estimated)